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Objectives: The examination of the effects of stress in university students dur-
ing the exam period, compared with demographic data. MethOds: Prospective 
research was made in the exam period. Altogether 181 university students par-
ticipated in the study, in the course of which online questionnaire were applied. 
In the first part of the questionnaire demographic questions were listed, while 
Student Nursing Stress Index (SNSI) questionnaire was applied to measure stress 
level. Emotions perceived in a given moment could be evaluated by the Brunel Mood 
Scale. In the last part of the questionnaire Marlowe- Crowne Senior Short Form 
Social Desirability Scale (MCSDS) was applied to evaluate behaviour desired by the 
society. The analysis of results was performed with SPSS 20.00 and MO Excel 2007 
programs. For data analysis descriptive statistics, χ 2-test, t-test, variance analy-
sis and regression analysis besides the significance level p< 0,05. Results: The 
division of genders was 28 (15,47%) male and 153 (84,53%) female participants in 
the research (n= 181). The average age was 21,62±3,07 years. The measurement of 
stress showed that sleeping time of students can be significantly affected by stress 
(p< 0,001). Those whose parents are divorced reached higher points in the value of 
stress (p= 0,038). Stress load caused by the exams did not show significant difference 
between specialities (p> 0,05). In the course of the research we found that senior 
students experienced significantly more stress in the exam period than freshmen 
(p= 0,013). cOnclusiOns: As the result of the measurements it can be said that 
stress is continuously present in students. Besides the requirements of the univer-
sity students have to cope with several other problems.
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Objectives: Medication non-adherence is often classified by the timing of non-
adherence. Primary non-adherence is the failure to fill a newly-prescribed medica-
tion (Rx). Rx non-persistence is the failure to continue therapy after the initial fill. A 
recent classification − early non-persistence (ENP) − is the failure to obtain the first 
prescribed refill of a new Rx (single dispensation only). In this meta-analytic review, 
we compare the rates of ENP across studies by four moderator dimensions: (1) chronic 
disease class; (2) symptomatic vs. asymptomatic chronic condition; (3) length of the 
baseline treatment-free interval; and (4) whether ENP estimates were adjusted for 
Rx switches. MethOds: Fifty-eight studies that contained data on ENP were identi-
fied using a PubMed literature search and searches of each article’s reference list. 
ENP rates were recorded for 91 distinct samples. ENP was defined as the failure to 
obtain the first prescribed refill within 30 days of the first-refill date. ENP rates were 
weighted by sample size and combined to provide pooled fixed effect size estimates 
for the moderator dimensions. Results: Across all samples, the overall weighted ENP 
rate was 23.6%. Observed difference between ENP rates by disease class were largely 
explained by whether the treatment focused on symptom control or not: symptomatic 
ENP rate= 39.5% vs. asymptomatic ENP rate= 17.7%. ENP rates were affected by two 
aspects of methodology: (1) length of baseline treatment-free interval (shorter, favor-
ing treatment-experienced= 17.1% vs. longer, favoring treatment-naïve= 27.2%); and (2) 
Rx switches accounted for in the ENP estimates (accounting for switch= 18.8% vs. not 
accounting for switch= 26.0%). cOnclusiOns: ENP is as high, and can be higher than 
primary non-adherence. Most extant studies simply document the rate of ENP. Given 
that ~ 24% of patients are “one-and-done,” it is imperative to: (1) understand the driv-
ers of ENP and (2) develop patient-centered interventions to stem the epidemic of ENP.
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Objectives: Lack of adherence and persistence can be major barriers to treatment 
efficiency in real world, for many chronic diseases. Measuring patients’ acceptance 
of their medication is thus gaining importance as it is likely to help better under-
stand and predict patients’ behavior towards treatment. The generic ACCEptance 
by the Patients of their Treatment (ACCEPT) questionnaire was developed to meas-
ure patients’ acceptance of their medication. The objective of this study was to 
evaluate for a variety of diseases the level of acceptance in real life using a patient 
online community. MethOds: This study was observational, cross-sectional, con-
ducted through the French Carenity platform. All patients connected were invited 
to complete an online questionnaire including demographics, chronic disease and 
treatment, and the 25 ACCEPT items. ACCEPT includes 6 multi-item acceptance 
dimensions (Medication Inconvenience, Long-term Treatment, Regimen Constraints, 
Side Effects, Effectiveness and General; range 0-100; higher score= greater accept-
ance) and one single-item acceptance dimension (Numerous Medications; range 
1-3). Patients included in the analysis were suffering from any chronic diseases 
with at least 50 respondents and currently receiving a treatment for this dis-
ease. Results: Responding patients had breast cancer (n= 57), type 1 diabetes 
(n= 101), type 2 diabetes (n= 213), fibromyalgia (n= 135), rheumatoid arthritis (n= 98), 
multiple sclerosis (n= 260), ankylosing spondylitis (n= 134) or bipolar disorder (n= 65). 
Most respondents were female (49% to 100%), with mean age 44 to 61. Mean (SD) 
ACCEPT General score was: 36 (33) for breast cancer, 64 (31) for type 1 diabetes, 54 
(32) for type 2 diabetes, 35 (31) for fibromyalgia, 39 (31) for rheumatoid arthritis, 50 
population consisted of older people (≥ 65 years) with polypharmacy (≥ 5 drugs) and 
the study was conducted in 178 community pharmacies in Spain. A total of 1,403 
patients were enrolled, 688 in the intervention group (IG) and 715 in the control 
group (CG). The analysis adopted the perspective of the National Health Service 
(NHS). In order to analyze the uncertainty of ICER results, we performed a non-
parametric bootstrapping with 5,000 replications. Results: Both groups reduced 
the average number of prescribed medications, although this reduction was greater 
in the IG (0.28 drugs; p< 0.001) than in the CG (0.07 drugs; p= 0.063). Patients in the 
IG showed an improvement in their quality of life by 0.0528 in the utility score 
(p< 0.001). By contrast, patients in the CG showed no differences in their quality of 
life by 0.0022 in the utility score (p= 0.815). We obtained an ICER of € 8,542/QALY and 
€ 6,777/QALY for the first and second scenario respectively, and a MRF as dominant 
strategy for the third, fourth and fifth scenario. For a willingness to pay of € 30,000/
QALY, the probability of the MRF being cost-effective, compared to usual dispensing, 
is in a range between 98.2% and 100% for the five scenarios. cOnclusiOns: MRF is 
an effective intervention for optimizing prescribed medication and improving the 
quality of life of older people with polypharmacy in community pharmacies. The 
results from the cost-utility analysis suggest that MRF is cost-effective.
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Objectives: To evaluate health care resource utilization and costs of patients 
diagnosed with Alzheimer’s disease (AD) and residing in long-term care facili-
ties. MethOds: A retrospective database analysis was performed using the 
Minimum Data set (MDS) linked to 5% Medicare data from 01JAN2008 through 
31DEC2011. AD patients were identified using International Classification of Disease, 
9thRevision, Clinical Modification (ICD-9-CM) diagnosis code 331.0. The first diag-
nosis date was designated as the index date. A comparison cohort was created for 
patients without an AD diagnosis, using 1: 1 propensity score matching (PSM) to con-
trol for baseline characteristics (age, region, gender, index year, baseline Charlson 
Comorbidity Index [CCI] score). For the comparison cohort, the index date was 
randomly chosen to reduce selection bias. Patients in both cohorts were required 
to be age ≥ 65 years, with at least two consecutive quarterly assessments in MDS 
data in the 6 months pre-index date and 1-year continuous medical and pharmacy 
benefits enrollment pre- and post-index date. Study outcomes (health care costs and 
utilizations) were compared between the cohorts. Results: After 1: 1 matching, a 
total of 2,158 patients were identified for the disease and comparison cohorts, and 
baseline characteristics were balanced. The AD cohort had a higher percentage of 
inpatient stays (33.73% vs. 24.93%, p< 0.0001), outpatient visits (92.22% vs. 89.99%, 
p= 0.01) and skilled nursing facility (SNF) (32.53% vs. 28.41%, p< 0.01) and hospice 
admissions (11.03% vs. 7.14%, p< 0.0001) than the comparison cohort. The AD cohort 
also incurred higher inpatient ($5,442 vs. $4,001, p< 0.001), SNF ($5,679 vs. $4,523, 
p< 0.01) and hospice stay costs ($3,164 vs. $2,047, p< 0.001) as well as carrier claim 
($2,907 vs. $2,686, p= 0.03) and pharmacy costs ($5,043 vs. $4,722, p= 0.01), compared 
to the comparison cohort. cOnclusiOns: AD was associated with higher health 
care resource utilization and a significantly higher economic burden.
IndIVIduaL’S HeaLtH – Patient-reported outcomes & Patient  
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Objectives: Medication-related non-adherence is a major challenge in the real-
life treatment of patients. To meet this challenge successfully, adherence inter-
ventions with a tailored approach towards patient-specific adherence barriers are 
needed. Therefore, a reliable and practicable questionnaire for identification of those 
adherence barriers in specific patients is needed. The aim of this investigation is 
to develop and validate such a questionnaire. MethOds: The “Adherence Barriers 
Questionnaire (ABQ)” was developed and tested in 432 patients with atrial fibrilla-
tion in a multicenter observational cohort study. Evaluation of the questionnaire 
included an assessment of internal consistency as well as factor analysis. Criterion-
related external validity was appraised by comparing the ABQ score with the score of 
a self-report adherence measure and with a clinical parameter (time in therapeutic 
range (TTR) regarding INR values in the VKA-based stroke prophylaxis treatment 
of patients). Results: The final 14-item ABQ scale demonstrated high internal 
consistency (Cronbach’s alpha= 0.820). Factor analysis identified a three-factor solu-
tion, representing intentional adherence barriers with 5 items (31.9% of the vari-
ance), medication- or health care system-related adherence barriers with 5 items 
(13.3% of the variance) and unintentional adherence barriers with 4 items (7.7% of 
the variance). The ABQ correlated significantly with self-reported non-adherence 
(Spearman’s rho= 0.438, P< 0.001) as well as TTR (Spearman’s rho= -0.161, P< 0.01). 
Patients with above-average ABQ scores (increased number of existing adherence 
barriers) were significantly (p< 0.005, Pearson Chi-Square) more likely to have a poor 
anticoagulation quality (TTR< 60%) than patients with a lower ABQ score (44.6% 
versus 27.3%). cOnclusiOns: The ABQ is a practicable, reliable and valid instrument 
for identifying specific barriers to medication-related adherence. Future research is 
required to examine the ability of the ABQ to identify patient perception/behavior 
changes over time which may be important for the measurement of success of adher-
ence interventions.
